STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRL
  4. [144] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SEC Filing

Charles River (NYSE: CRL) investor to sell 573 shares via UBS

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is the issuer for which a holder, Nancy C. Andrews, has filed a notice of proposed sale under Rule 144. The notice covers the potential sale of 573 shares of common stock, with an aggregate market value of 163,305, out of 48,167,730 shares outstanding, through UBS Financial Services Inc., with an approximate sale date of 08/18/2026 following a stock option exercise.

Positive

  • None.

Negative

  • None.
Shares to be sold 573 shares Number of CRL common shares covered by the Rule 144 notice
Aggregate market value 163,305 Aggregate market value of the 573 CRL shares to be sold
Shares outstanding 48,167,730 shares CRL common shares outstanding referenced in the Rule 144 notice
Approximate sale date 08/18/2026 Approximate date of proposed sale of the 573 CRL shares
Acquisition date 08/18/2026 Date of stock option exercise through which the 573 shares were acquired
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
stock option exercise financial
"Common Stock | 08/18/2026 | Stock Option Exercise | Charles River Laboratories"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
attorney-in-fact regulatory
"for UBS Financial Services Inc, as attorney-in-fact for Nancy C Andrews"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing for CRL disclose about planned share sales?
The filing discloses a planned sale of 573 CRL common shares under Rule 144. These shares are held for the account of Nancy C. Andrews and are expected to be sold through UBS Financial Services Inc. around 08/18/2026.

How many Charles River Laboratories (CRL) shares are covered by this Form 144?
The notice covers 573 shares of Charles River Laboratories common stock. This amount is small compared with the reported 48,167,730 shares outstanding, indicating a limited relative size for this proposed sale.

What is the aggregate market value of the CRL shares in this Form 144?
The aggregate market value of the 573 CRL shares covered is listed as 163,305. This figure reflects the total market value of the shares proposed to be sold under Rule 144 at the time of the notice.

When are the CRL shares in this Form 144 expected to be sold?
The approximate sale date indicated is 08/18/2026. This date applies to the proposed Rule 144 sale of the 573 CRL common shares, which are associated with a stock option exercise paid for in cash.

How were the CRL shares in this Form 144 acquired?
The 573 CRL shares were acquired via a stock option exercise on 08/18/2026, with the consideration paid in cash. After exercise, a notice was filed to permit their potential resale under Rule 144.

Who is executing the planned Rule 144 sale of CRL shares?
The proposed sale is to be executed through UBS Financial Services Inc.. UBS is listed as the broker for the Rule 144 transaction involving 573 Charles River Laboratories common shares held for Nancy C. Andrews’ account.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR